REGULARISATION OF APPOINTMENT OF MR. SHALENDRA PATHAK AFTER THE APPROVAL FROM SHAREHOLDERS AS WHOLE TIME DIRECTOR OF THE COMPANY IN THE EGM HELD ON 11.05.2026
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Shareholders of Beryl Drugs Ltd approved the regularisation of Mr. Shailendra Pathak as Whole-Time Director at an EGM held on 11 May 2026. He was initially appointed as Additional Director and Whole-Time Director by the Board on 3 January 2026, and this appointment required shareholder approval under the Companies Act, 2013. Mr. Pathak is an Engineer with over 35 years of experience in the pharmaceutical industry, specialising in IV fluids and Oral Solid Doses manufacturing. His appointment is for 5 years with a fixed monthly remuneration of Rs. 1,25,000 plus commission on sales. He is not related to any existing Director and is not debarred from holding office.
This is a routine corporate governance action to formalise an existing director appointment. The appointment brings an experienced pharmaceutical industry veteran to the Board, which could be positive for operational oversight, but does not materially impact stock valuation in the near term.